Lung Cancer

Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.

Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.

Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.

The partial clinical hold placed on the phase 2 IOV-LUN-202 trial of LN-145 in non–small cell lung cancer has been lifted by the FDA.

MAAs for datopotamab deruxtecan in non–small cell lung cancer and hormone receptor–positive, HER2-negative breast cancer have been validated by the EMA.

Nisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.

The FDA has approved amivantamab plus chemotherapy for the frontline treatment of select patients with EGFR exon 20 insertion+ non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the movement of targeted and immune therapies in non–small cell lung cancer treatment.

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.